Organon & Co. Indenture Agreements

8 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Supplemental Indenture to 7.875% Senior Notes Due 2034 Among Organon Entities, Dermavant Sciences, and U.S. Bank Trust Company
Indenture Agreements
Organon & Co.
Pharmaceuticals
NY
2025
Supplemental Indenture to 6.750% Senior Secured Notes Due 2034 Among Organon Entities, Dermavant Sciences, and U.S. Bank Trust Company
Indenture Agreements
Organon & Co.
Pharmaceuticals
NY
2025
Fourth Supplemental Indenture to 5.125% Senior Notes Due 2031 by Organon & Co. and Subsidiaries
Indenture Agreements
Organon & Co.
Pharmaceuticals
NY
2025
Fourth Supplemental Indenture to 4.125% Senior Secured Notes Due 2028—Organon & Co. and Subsidiaries
Indenture Agreements
Organon & Co.
Pharmaceuticals
NY
2025
Fourth Supplemental Indenture to 2.875% Senior Secured Notes Due 2028—Organon & Co. and Subsidiaries
Indenture Agreements
Organon & Co.
Pharmaceuticals
NY
2025
Third Supplemental Indenture to 5.125% Senior Notes Due 2031—Alydia Health, Inc., Organon & Co., Organon Foreign Debt Co-Issuer B.V., and U.S. Bank National Association
Indenture Agreements
Organon & Co.
Pharmaceuticals
NY
2025
Third Supplemental Indenture among Alydia Health, Inc., Organon & Co., Organon Foreign Debt Co-Issuer B.V., and U.S. Bank National Association (July 30, 2021)
Indenture Agreements
Organon & Co.
Pharmaceuticals
NY
2025
Third Supplemental Indenture to 2.875% Senior Secured Notes Due 2028 – Alydia Health, Inc., Organon & Co., Organon Foreign Debt Co-Issuer B.V., and U.S. Bank National Association
Indenture Agreements
Organon & Co.
Pharmaceuticals
NY
2025